[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100335693":3},{"organization":4,"armGroups":7,"interventions":14,"overallOfficials":23,"centralContacts":24,"locations":33,"responsibleParty":51,"collaborators":23,"id":53,"slug":54,"hasResults":55,"nctId":56,"briefTitle":57,"officialTitle":58,"acronym":23,"eligibilityCriteria":59,"healthyVolunteers":55,"sex":60,"minAge":61,"maxAge":23,"enrollmentInfo":62,"targetDuration":23,"studyType":65,"phases":66,"briefSummary":68,"conditions":69,"keywords":23,"overallStatus":71,"whyStopped":23,"lastUpdateSubmitDate":72,"lastUpdatePostDateStruct":73,"startDateStruct":76,"completionDateStruct":78,"leadSponsor":80,"locationsCount":81},{"fullName":5,"class":6},"The First Affiliated Hospital with Nanjing Medical University","OTHER",[8],{"label":9,"type":10,"description":11,"interventionNames":12},"Study group","EXPERIMENTAL","apatinib 250mg oral d1-21; albumin paclitaxel 260mg\u002Fm2 intravenous drip d1; carboplatin AUC=5-6 intravenous drip d1; 21 days for 1 cycle. The treatment regimen was used for a total of 6 cycles, or to PD, or the toxicity was not tolerated.",[13],"Drug: Apatinib",[15],{"type":16,"name":17,"description":18,"armGroupLabels":19,"otherNames":20},"DRUG","Apatinib","Neoadjuvant program: apatinib 250mg oral d1-21; albumin paclitaxel 260mg\u002Fm2 intravenous drip d1; carboplatin AUC=5-6 intravenous drip d1; 21 days for 1 cycle. The treatment regimen was used for a total of 6 cycles, or to PD, or the toxicity was not tolerated.",[9],[21,22],"Carboplatin","albumin paclitaxel",null,[25,30],{"name":26,"role":27,"phone":28,"phoneExt":23,"email":29},"Li Wei","CONTACT","13851603656","real.lw@163.com",{"name":31,"role":27,"phone":32,"phoneExt":23,"email":23},"Yin Yongmei","13951842727",[34],{"facility":35,"status":36,"city":37,"state":38,"zip":39,"country":40,"countryCode":41,"cosmosGeoPoint":42,"geoPoint":47,"contacts":48},"Jiangsu Provincial Hospital","RECRUITING","Nanjing","Jiangsu","210000","China","CN",{"type":43,"coordinates":44},"Point",[45,46],118.77778,32.06167,{"lat":46,"lon":45},[49],{"name":50,"role":27,"phone":23,"phoneExt":23,"email":23},"Tang Jinhai",{"type":52,"investigatorFullName":23,"investigatorTitle":23,"investigatorAffiliation":23,"oldNameTitle":23,"oldOrganization":23},"SPONSOR","100335693","phase-2-this-study-was-a-prospective-one-arm-open-phase-ii-clinical-trial-a-systematic-review-of-the-pcr-of-apatinib-in-combination-with-the-albumin-paclitaxel-and-carboplatin-regimens-for-the-neoadjuvant-therapy-of-triple-negative-breast-cancer-as-well-as-the-safety-of-treatment-100335693",false,"NCT03650738","This Study Was a Prospective, One-arm Open Phase II Clinical Trial. A Systematic Review of the pCR of Apatinib in Combination With the Albumin Paclitaxel and Carboplatin Regimens for the Neoadjuvant Therapy of Triple-negative Breast Cancer, as Well as the Safety of Treatment","A Prospective, One-arm Open Clinical Trial of Apatinib Combined With Albumin Paclitaxel and Carboplatin as a Neoadjuvant Therapy for the Safety and Efficacy of Triple-negative Breast Cancer","Inclusion Criteria:\n\n* 1\\. The patient volunteers and signs an informed consent form. 2.age ≥18 years old, female; 3.Diagnosed as triple negative breast cancer by histopathology; 4.Did not receive systemic anti-tumor treatment; 5. The clinical stage is stage II-III; 6.There must be at least one measurable lesion (according to RECIST v1.1); 7.Physical condition ECOG PS: 0-1; 8.Expected survival time ≥ 3 months; 9.Laboratory tests meet the following criteria: Bone marrow function: absolute count of blood neutrophils (ANC) ≥1.5×109\u002FL; platelet (PLT)≥100×109\u002FL; hemoglobin (HB)≥90g\u002FL; Liver function: serum total bilirubin (STB), combined bilirubin (CB) ≤ upper limit of normal (ULN) \\*1.5; alanine aminotransferase (ALT), aspartate aminotransferase (AST) ≤ULN\\*2.5; Renal function: serum creatinine (Cr) ≤ ULN; endogenous creatinine clearance (Ccr) ≥ 60 ml \u002F min (calculated using the Cockcroft-Gault formula);\n\nExclusion Criteria:\n\n* 1.Major surgery within 4 weeks prior to enrollment, or surgical wounds have not healed; 2.Embolization and bleeding occurred within 4 weeks before enrollment; 3.Malignant tumors of other histological origins in the past 5 years, except for cured cervical carcinoma in situ and basal cell carcinoma or squamous cell carcinoma; 4.Severe cardiovascular disease, including hypertension (BP≥160\u002F95mmHg) uncontrolled by medical treatment, unstable angina, history of myocardial infarction in the past 6 months, congestive heart failure\\>NYHA II, severe heart rhythm Abnormalities and pericardial effusions; 5.Severe infection requires intravenous antibiotic, antifungal or antiviral treatment; 6.Suffering from mental illness, poor compliance; 7.Researchers believe that it is not suitable for inclusion.","FEMALE","18 Years",{"count":63,"type":64},60,"ESTIMATED","INTERVENTIONAL",[67],"PHASE2","This study was a prospective, one-arm open phase II clinical trial. A systematic review of the pCR of apatinib in combination with the albumin paclitaxel and carboplatin regimens for the neoadjuvant therapy of triple-negative breast cancer, as well as the safety of treatment, at the same time, relevant exploratory biomarker research is conducted.",[70],"Systematic Review of the pCR Rate of Apatinib Combined With Albumin Paclitaxel and Carboplatin Regimen for Neoadjuvant Therapy of Triple-negative Breast Cancer","UNKNOWN","2018-08-28",{"date":74,"type":75},"2018-08-29","ACTUAL",{"date":77,"type":64},"2018-09-01",{"date":79,"type":64},"2019-12-31",{"name":5,"class":6},1]